Daniel F. Martin, MD, Chair, Cole Eye Institute, discusses key five-year findings from the Comparison of AMD Treatments Trials (CATT) study at ARVO 2016.
Long-acting drug delivery ocular implants are being studied at Cole Eye Institute as a viable option to replace frequent injections and office visits.
New Cleveland Clinic research shows that serial hepatic USG — paired with confirmatory CT/MRI scans when needed — has high sensitivity and specificity for detecting asymptomatic uveal melanoma metastases.
Cleveland Clinic researchers demonstrate cell-specific responses to extracellular viruses, which may be helpful in uncovering the mechanisms behind determining a cell’s fate.
Risk of blindness is a side effect of hydroxychloroquine, a common drug for RA and lupus, but rates of adequate screening for toxicity could be improved.
Eyebrow ptosis commonly accompanies aging. Despite having complex causes, it can be repaired with a simple frontalis muscle transposition flap, say doctors at Cleveland Clinic’s Cole Eye Institute.
Some practitioners avoid Botox injections rather than risk blepharoptosis or diplopia. However, data show that injections in the central eyelid and brow areas are a safe option for chemodenervation, Cleveland Clinic researchers report.
The biology of how blood vessels in the retina and choroid develop is helping scientists examine abnormal angiogenesis and how to identify potential therapeutic approaches to prevent or reverse it.
Zebrafish are naturally able to heal damaged retinas and prevent scarring that can lead to loss of vision. Cleveland Clinic researchers hope to learn how to replicate that process in the human eye.
Ongoing global analyses can identify biomarker candidates for targeted quantitative proteomic analyses. Knowledge gained can guide future diagnoses and treatments for AMD and glaucoma.